Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines an
The marketing authorisation for Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostic expired on 28 November 2015 following the decision of the marketing authorisation holder, Novartis Vaccines and Diagnostics S.r.l., not to apply for a renewal of the marketing authorisation. The vaccine contained haemagglutinin and neuraminidase of influenza virus H5N1 A/Vietnam/1194/2004.
Click on this link for more information.
